Dr. Oh Discusses Immunotherapy in Prostate Cancer

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

It is known that prostate cancer is not going to be like other diseases, such as melanoma or lung cancer, where there are high response rates to immunotherapy. However, there is hope that combinations will make a difference, particularly combinations with vaccines, such as sipuleucel-T and checkpoint inhibitors.